Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.

Tugnait M, Gupta N, Hanley MJ, Sonnichsen D, Kerstein D, Dorer DJ, Venkatakrishnan K, Narasimhan N.

Clin Pharmacol Drug Dev. 2019 Jul 9. doi: 10.1002/cpdd.723. [Epub ahead of print]

PMID:
31287236
2.

The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.

Tugnait M, Gupta N, Hanley MJ, Venkatakrishnan K, Sonnichsen D, Kerstein D, Dorer DJ, Narasimhan N.

Clin Pharmacol Drug Dev. 2019 Aug;8(6):734-741. doi: 10.1002/cpdd.641. Epub 2018 Dec 20.

3.

Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.

Narasimhan NI, Dorer DJ, Davis J, Turner CD, Sonnichsen D.

Clin Pharmacol Drug Dev. 2015 Sep;4(5):354-60. doi: 10.1002/cpdd.182. Epub 2015 May 1.

PMID:
27137144
4.

Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.

Abbas R, Boni J, Sonnichsen D.

Drug Metab Pers Ther. 2015 Mar;30(1):57-63. doi: 10.1515/dmdi-2014-0026.

PMID:
25803093
5.

Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects.

Narasimhan NI, Dorer DJ, Davis J, Turner CD, Sonnichsen D.

Clin Drug Investig. 2014 Oct;34(10):723-9. doi: 10.1007/s40261-014-0225-y.

PMID:
25145453
6.

Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.

Narasimhan NI, Dorer DJ, Davis J, Turner CD, Marbury TC, Sonnichsen D.

Cancer Chemother Pharmacol. 2014 Aug;74(2):341-8. doi: 10.1007/s00280-014-2511-z. Epub 2014 Jun 17.

PMID:
24934866
7.

Effects of food on the pharmacokinetics of ponatinib in healthy subjects.

Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D.

J Clin Pharm Ther. 2013 Dec;38(6):440-4. doi: 10.1111/jcpt.12082. Epub 2013 Jul 25.

8.

A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.

Abbas R, Leister C, Sonnichsen D.

Clin Drug Investig. 2013 Aug;33(8):589-95. doi: 10.1007/s40261-013-0103-z.

PMID:
23839484
9.

Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects.

Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D.

J Clin Pharmacol. 2013 Sep;53(9):974-81. doi: 10.1002/jcph.109. Epub 2013 Jun 25.

10.

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.

Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1599-607. doi: 10.1007/s00280-013-2160-7. Epub 2013 Apr 23.

11.

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.

Abbas R, Chalon S, Leister C, El Gaaloul M, Sonnichsen D.

Cancer Chemother Pharmacol. 2013 Jan;71(1):123-32. doi: 10.1007/s00280-012-1987-7. Epub 2012 Sep 30.

PMID:
23053269
12.

Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.

Abbas R, Leister C, El Gaaloul M, Chalon S, Sonnichsen D.

Clin Ther. 2012 Sep;34(9):2011-9.e1. doi: 10.1016/j.clinthera.2012.07.006. Epub 2012 Aug 9.

PMID:
22884766
13.
14.

A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.

Boni JP, Leister C, Hug B, Burns J, Sonnichsen D.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1433-42. doi: 10.1007/s00280-012-1845-7. Epub 2012 Feb 26.

PMID:
22367193
15.
16.

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D.

Cancer Chemother Pharmacol. 2012 Jan;69(1):221-7. doi: 10.1007/s00280-011-1688-7. Epub 2011 Jun 21.

PMID:
21691746
17.

Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.

Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D.

Br J Clin Pharmacol. 2011 Apr;71(4):522-7. doi: 10.1111/j.1365-2125.2010.03845.x.

18.

Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.

Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D.

J Clin Pharmacol. 2011 Dec;51(12):1721-7. doi: 10.1177/0091270010387427. Epub 2010 Dec 8.

PMID:
21148045
19.

A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.

Hug B, Abbas R, Leister C, Burns J, Sonnichsen D.

Clin Cancer Res. 2010 Aug 1;16(15):4016-23. doi: 10.1158/1078-0432.CCR-10-0280. Epub 2010 Jul 20.

20.

Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.

Boni JP, Hug B, Leister C, Sonnichsen D.

Semin Oncol. 2009 Dec;36 Suppl 3:S18-25. doi: 10.1053/j.seminoncol.2009.10.009. Review.

PMID:
19963096
21.

Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.

Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM.

Clin Cancer Res. 2009 Nov 1;15(21):6709-15. doi: 10.1158/1078-0432.CCR-09-0536. Epub 2009 Oct 13.

22.

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.

Eder JP Jr, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG.

Cancer Chemother Pharmacol. 2006 Jul;58(1):107-16. Epub 2005 Dec 13.

PMID:
16362299
23.

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.

Ryan DP, Eder JP Jr, Puchlaski T, Seiden MV, Lynch TJ, Fuchs CS, Amrein PC, Sonnichsen D, Supko JG, Clark JW.

Clin Cancer Res. 2004 Apr 1;10(7):2222-30.

24.

A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer.

Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J, Hurwitz H.

Clin Cancer Res. 2004 Mar 15;10(6):1963-70.

25.

A review and assessment of potential sources of ethnic differences in drug responsiveness.

Bjornsson TD, Wagner JA, Donahue SR, Harper D, Karim A, Khouri MS, Murphy WR, Roman K, Schneck D, Sonnichsen DS, Stalker DJ, Wise SD, Dombey S, Loew C.

J Clin Pharmacol. 2003 Sep;43(9):943-67. Review.

PMID:
12971027
26.

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, Fojo T.

J Clin Oncol. 2003 May 1;21(9):1866-73.

PMID:
12721265
27.

Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study.

McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB.

Clin Cancer Res. 2002 Jul;8(7):2035-43.

28.

Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.

Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J Jr, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen DS, Skillings J, Rowinsky EK.

J Clin Oncol. 2001 May 1;19(9):2493-503.

PMID:
11331328
29.

Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.

Damle B, Ravandi F, Kaul S, Sonnichsen D, Ferreira I, Brooks D, Stewart D, Alberts D, Pazdur R.

Clin Cancer Res. 2001 Mar;7(3):517-23.

30.

Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias.

Woo MH, Relling MV, Sonnichsen DS, Rivera GK, Pratt CB, Pui CH, Evans WE, Pappo AS.

Clin Cancer Res. 1999 Mar;5(3):543-9.

31.

Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.

Meropol NJ, Sonnichsen DS, Birkhofer MJ, Ferreira I, Noel D.

Cancer Chemother Pharmacol. 1999;43(3):221-6. Erratum in: Cancer Chemother Pharmacol 2001 Mar;47(3):282.

PMID:
9923552
32.

Clinically significant cytochrome P-450 drug interactions--a comment.

Ford NF, Sonnichsen DS.

Pharmacotherapy. 1998 Jul-Aug;18(4):890-1; discussion 892-3. No abstract available.

PMID:
9692671
33.

Oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer.

Meropol NJ, Noel D, Sonnichsen DS, Birkhofer MJ.

Oncology (Williston Park). 1997 Sep;11(9 Suppl 10):22-5.

34.

Variability in human cytochrome P450 paclitaxel metabolism.

Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV.

J Pharmacol Exp Ther. 1995 Nov;275(2):566-75.

PMID:
7473140
35.

Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.

Sonnichsen DS, Ribeiro RC, Luo X, Mathew P, Relling MV.

Clin Pharmacol Ther. 1995 Jul;58(1):99-107.

PMID:
7628187
36.

Clinical pharmacokinetics of paclitaxel.

Sonnichsen DS, Relling MV.

Clin Pharmacokinet. 1994 Oct;27(4):256-69. Review.

PMID:
7834963
37.

Phase I study of oral etoposide in children with refractory solid tumors.

Mathew P, Ribeiro RC, Sonnichsen D, Relling M, Pratt C, Mahmoud H, Bowman L, Meyer W, Avery L, Crist W.

J Clin Oncol. 1994 Jul;12(7):1452-7.

PMID:
8021737
38.

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.

Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV.

J Clin Oncol. 1994 Mar;12(3):532-8.

PMID:
7907130

Supplemental Content

Loading ...
Support Center